换一批骨髓增殖性肿瘤治疗进展:第56届美国血液学会年会报道
Treatment advances in myeloproliferative neoplasms: reports from the 56th American Society of Hematology annual meeting
摘要近年对bcr-abl阴性的骨髓增殖性肿瘤的发病机制、诊断、风险分层及治疗等方面的研究取得了长足进展,文章就2014年第56届美国血液学会(ASH)年会上关于bcr-abl阴性的骨髓增殖性肿瘤治疗进展等内容作一介绍.
更多相关知识
abstractsGreat advances have been made in understanding the pathogenesis,diagnosis,risk stratification and treatment of classic bcr-abl-negative myeloproliferative neoplasms (MPN).This article reviews current situation in the treatment of these MPNs presented in the 56th American Society of Hematology (ASH) annual meeting.
More相关知识
关键词
骨髓增殖性肿瘤羟基脲干扰素JAK抑制剂靶向治疗美国血液学会年会Myeloproliferative neoplasmHydroxycarbamideInterferonJAK inhibitorsTargeted treatmentAmerican Society of Hematology annual meeting
栏目名称
DOI
10.3760/cma.j.issn.1009-9921.2015.04.001
发布时间
2015-06-08（万方平台首次上网日期，不代表论文的发表时间）
- 浏览318
- 被引0
- 下载176
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
